Sandoz agrees to $478.5 million settlement over generic drug price-fixing claims
Sandoz will pay $478.5 million to resolve accusations that it colluded to raise generic drug prices, settling claims from U.S. states and reseller class actions.
Sandoz has reached a settlement totaling $478.5 million to address allegations that it participated in a broad scheme to inflate prices of generic medicines, harming consumers and limiting competition. Under the agreement, the company will disburse $400 million over a seven-year period starting in 2027 to resolve all outstanding claims from U.S. states in three ongoing cases, and will also make a roughly $50 million payment to states that settled earlier.
An additional $28.5 million will be paid to end all remaining class-action litigation brought by indirect resellers. The company maintains that it did not engage in any illegal conduct. This settlement adds to a series of recent resolutions in the generic drug sector, including deals by Glenmark Pharmaceuticals, Lannett, Bausch, Apotex and Heritage Pharmaceuticals that together amounted to about $98 million.
Why it matters
The settlement highlights ongoing scrutiny of drug pricing practices that affect medication costs for consumers nationwide.
In this story